The trial confirmed that the vaccine was well-tolerated and recognized no security considerations, the company stated. An unbiased committee “found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine,” based on AstraZeneca.
The new information got here from a Phase 3 medical trial carried out within the US, Chile and Peru. AstraZeneca says it plans to submit the findings to a scientific journal for peer evaluation.
For its half, Oxford stated the findings add “to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom” based on a press launch from the college.
As a part of the trial, greater than 32,000 volunteers recruited throughout all ages acquired both two doses of the vaccine or a placebo vaccine at a four-week interval.
An emergency investigation by the European Medicines Agency (EMA) got here to the conclusion final Thursday that the vaccine is “safe and effective” in stopping coronavirus and “not associated with an increase in the overall risk of thromboembolic events, or blood clots.”
Co-designer of the vaccine and professor of Vaccinology at Oxford University Sarah Gilbert hailed the info for offering “further confirmation of the safety and effectiveness” of the vaccine.
Lead Investigator for the vaccine and professor of Paediatric Infection and Immunity at Oxford University Andrew Pollard stated the AstraZeneca information was “consistent with the results from Oxford-led trials”, including that he anticipated a “strong impact against COVID-19 across all ages and for people of all different backgrounds from widespread use of the vaccine.”